128 related articles for article (PubMed ID: 1680941)
41. Pros and cons of gynecologic tumor markers.
Bast RC; Hunter V; Knapp RC
Cancer; 1987 Oct; 60(8 Suppl):1984-92. PubMed ID: 2443235
[TBL] [Abstract][Full Text] [Related]
42. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies.
O'Connor JF; Schlatterer JP; Birken S; Krichevsky A; Armstrong EG; McMahon D; Canfield RE
Cancer Res; 1988 Mar; 48(5):1361-6. PubMed ID: 2449279
[TBL] [Abstract][Full Text] [Related]
43. Role of tumour markers, cytogenetics.
Lamerz R
Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
[TBL] [Abstract][Full Text] [Related]
44. [The clinical evaluation of sialyl Lewis Xi antigen in patients with gynecologic tumors].
Shimizu C; Inoue M; Sasagawa T; Shimizu H; Ueda G; Tanizawa O
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1393-8. PubMed ID: 2572654
[TBL] [Abstract][Full Text] [Related]
45. Similarity and co-expression of tumour-associated antigens recognised by different monoclonal antibodies.
Sakahara H; Saga T; Endo K; Kousaka T; Hosono M; Kobayashi H; Shirato M; Konishi J
Br J Cancer; 1993 Nov; 68(5):920-5. PubMed ID: 8217607
[TBL] [Abstract][Full Text] [Related]
46. Sialyl Lewis-Xi antigen in patients with gynecologic tumors.
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O
Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045
[TBL] [Abstract][Full Text] [Related]
47. [A statistical analysis of serum sialyl Lewis X-1 (SLX), CEA, SCC and NSE levels in patients with lung cancer].
Ueoka H; Ohnoshi T; Moritaka T; Kiura K; Mima Y; Horiguchi T; Segawa Y; Tabata M; Shibayama T; Maeda T
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Aug; 29(8):1022-8. PubMed ID: 1684395
[TBL] [Abstract][Full Text] [Related]
48. [Establishment and characterization of a human chorionic gonadotropin (hCG) producing cell line (RTSG) from an ovarian epithelial cancer].
Udagawa Y; Nozawa S; Chin K; Sakayori M; Mikami M; Ohta K; Tsukazaki K; Kiguchi K; Iizuka R
Hum Cell; 1990 Mar; 3(1):70-5. PubMed ID: 2083225
[TBL] [Abstract][Full Text] [Related]
49. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
50. [Biological function of cancer-associated carbohydrate antigens].
Kannagi R
Nihon Rinsho; 1996 Jun; 54(6):1551-9. PubMed ID: 8691608
[TBL] [Abstract][Full Text] [Related]
51. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
52. [A case of thymic cyst showing elevated CEA, SLX and CA125 levels in the cystic fluid associated with non-invasive thymoma].
Gotoh T; Tanaka T; Tsujimoto S; Toda S; Hashikura H; Arimoto T; Iwasaki Y; Nakamura T; Nakagawa M
Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Apr; 32(4):364-9. PubMed ID: 7913733
[TBL] [Abstract][Full Text] [Related]
53. [Sialyl Lewis(x)-I (SLX) as a tumor-associated carbohydrate antigen in sera in patients with gastric and colorectal cancer--evaluation according to clinico-pathological factors].
Nakagoe T; Ishikawa H; Nakao H; Satoh T; Miyashita K; Yokota M; Takahira R; Kusano H; Shimizu T; Fukuda Y
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):819-25. PubMed ID: 2565704
[TBL] [Abstract][Full Text] [Related]
54. Clinical use of gynaecologic tumour markers.
Halila H; Alfthan H; Stenman UH
Ann Chir Gynaecol; 1989; 78(1):65-70. PubMed ID: 2547331
[TBL] [Abstract][Full Text] [Related]
55. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
56. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
[TBL] [Abstract][Full Text] [Related]
57. [Diagnostic significance of tumor markers for gynecologic malignancies].
Aoki D; Hirasawa A; Susumu N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
[TBL] [Abstract][Full Text] [Related]
58. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
59. Clinical value of sialyl SSEA-1 antigen in patients with ovarian cancer.
Suzuki M; Ohwada M; Tamada T
Gynecol Oncol; 1990 Mar; 36(3):371-5. PubMed ID: 1969379
[TBL] [Abstract][Full Text] [Related]
60. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
Ito K; Udagawa Y; Nozawa S
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
